NasdaqCM:BCLI

Stock Analysis Report

Executive Summary

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of central nervous system (CNS) adult stem cell therapies designed to address the unmet medical needs of patients with debilitating neurodegenerative diseases.

Rewards

Earnings are forecast to grow 60.27% per year

Risk Analysis

Has less than 1 year of cash runway

Shareholders have been diluted in the past year

Does not have a meaningful market cap ($98M)



Snowflake Analysis

Moderate growth potential with worrying balance sheet.

Share Price & News

How has Brainstorm Cell Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: BCLI has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

-4.8%

BCLI

-4.1%

US Biotechs

-1.3%

US Market


1 Year Return

16.9%

BCLI

8.2%

US Biotechs

22.0%

US Market

Return vs Industry: BCLI exceeded the US Biotechs industry which returned 10.9% over the past year.

Return vs Market: BCLI underperformed the US Market which returned 24.2% over the past year.


Shareholder returns

BCLIIndustryMarket
7 Day-4.8%-4.1%-1.3%
30 Day1.2%-3.5%1.6%
90 Day10.7%11.7%8.9%
1 Year16.9%16.9%9.2%8.2%24.7%22.0%
3 Year46.3%46.3%23.3%19.2%49.4%39.7%
5 Year3.8%3.8%1.0%-3.8%78.1%58.5%

Price Volatility Vs. Market

How volatile is Brainstorm Cell Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Brainstorm Cell Therapeutics undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Brainstorm Cell Therapeutics is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Brainstorm Cell Therapeutics has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

Future Growth

How is Brainstorm Cell Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

60.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: BCLI is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.7%).

Earnings vs Market: BCLI is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: BCLI's is expected to become profitable in the next 3 years.

Revenue vs Market: Insufficient data to determine if BCLI's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if BCLI's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if BCLI's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Brainstorm Cell Therapeutics performed over the past 5 years?

-15.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: BCLI is currently unprofitable.

Growing Profit Margin: BCLI is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: BCLI is unprofitable, and losses have increased over the past 5 years at a rate of -15.6% per year.

Accelerating Growth: Unable to compare BCLI's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BCLI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (103.3%).


Return on Equity

High ROE: BCLI's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Brainstorm Cell Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: BCLI has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: BCLI has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: BCLI is debt free.

Reducing Debt: BCLI's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet

Inventory Level: BCLI has a high level of physical assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if BCLI's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: BCLI has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: BCLI has less than a year of cash runway if free cash flow continues to reduce at historical rates of -47.1% each year


Next Steps

Dividend

What is Brainstorm Cell Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage2.1%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate BCLI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate BCLI's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BCLI's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BCLI's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of BCLI's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Brainstorm Cell Therapeutics's salary, the management and board of directors tenure and is there insider trading?

2.2yrs

Average management tenure


CEO

Chaim Lebovits (48yo)

4.3yrs

Tenure

US$1,578,870

Compensation

Mr. Chaim Lebovits has been the Chief Executive Officer of Brainstorm Cell Therapeutics Inc. since September 22, 2015 and as its President since July 3, 2007. Mr. Lebovits serves as the Chief Executive Off ...


CEO Compensation Analysis

Compensation vs Market: Chaim's total compensation ($USD1.58M) is above average for companies of similar size in the US market ($USD519.76K).

Compensation vs Earnings: Chaim's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

2.2yrs

Average Tenure

48yo

Average Age

Experienced Management: BCLI's management team is considered experienced (2.2 years average tenure).


Board Age and Tenure

8.6yrs

Average Tenure

66.5yo

Average Age

Experienced Board: BCLI's board of directors are considered experienced (8.6 years average tenure).


Insider Trading

Insider Buying: BCLI insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyUS$11,64027 Dec 19
Ralph Kern
EntityIndividual
Role
Chief Operating Officer
COO & Chief Medical Officer
Shares3,000
Max PriceUS$3.88
BuyUS$45,92927 Dec 19
Preetam Shah
EntityIndividual
Role
Chief Financial Officer
Executive VP
Shares11,600
Max PriceUS$3.96
BuyUS$11,70027 Dec 19
Arturo Araya
EntityIndividual
Role
Senior Key Executive
Chief Commercial Officer
Shares3,000
Max PriceUS$3.90
SellUS$43,81821 Nov 19
Joseph Daly
EntityIndividual
Shares11,220
Max PriceUS$3.92
BuyUS$1,627,83821 Nov 19
Joseph Daly
EntityIndividual
Shares449,401
Max PriceUS$3.66
SellUS$42,30921 Nov 19
Karina Daly
EntityIndividual
Shares10,818
Max PriceUS$3.97
BuyUS$46,39321 Nov 19
Essig Research, Inc.
EntityCompany
Shares12,565
Max PriceUS$3.70

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 9.5%.


Management Team

  • Irit Arbel (59yo)

    Founder & Independent Chairperson

    • Tenure: 5.8yrs
    • Compensation: US$66.04k
  • Tom Rosedale

    Secretary

    • Daniel Offen

      Chief Scientific Advisor

      • Chaim Lebovits (48yo)

        President & CEO

        • Tenure: 4.3yrs
        • Compensation: US$1.58m
      • Yael Gothelf

        Vice President of Scientific & Regulatory Affairs

        • Uri Yablonka (42yo)

          Executive VP

          • Tenure: 5.6yrs
          • Compensation: US$34.76k
        • Arturo Araya (48yo)

          Chief Commercial Officer

          • Tenure: 1.3yrs
          • Compensation: US$20.44k
        • Ralph Kern (61yo)

          COO & Chief Medical Officer

          • Tenure: 2.8yrs
          • Compensation: US$841.65k
        • Susan Ward

          Head of Clinical Operations

          • Tenure: 1.6yrs
        • Preetam Shah (47yo)

          Executive VP

          • Tenure: 0.3yrs

        Board Members

        • Jacob Frenkel (76yo)

          Member of Business Advisory Board

          • Tenure: 12.4yrs
        • Chen Schor (47yo)

          Director

          • Tenure: 8.4yrs
          • Compensation: US$36.22k
        • Harvey Krueger (89yo)

          Member of Business Advisory Board

          • Tenure: 12.4yrs
        • Irit Arbel (59yo)

          Founder & Independent Chairperson

          • Tenure: 5.8yrs
          • Compensation: US$66.04k
        • Andy Card (71yo)

          Member of Business Advisory Board

          • Tenure: 8.8yrs
        • Malcolm Taub (73yo)

          Independent Director

          • Tenure: 10.8yrs
          • Compensation: US$37.32k
        • Rasheda Ali

          Member of Business Advisory Board

          • Tenure: 12.3yrs
        • Jerold Chun

          Chairman of Scientific Advisory Board

          • Tenure: 1.8yrs
        • June Almenoff (62yo)

          Independent Director

          • Tenure: 2.9yrs
          • Compensation: US$30.00k
        • Uri Yablonka (42yo)

          Executive VP

          • Tenure: 5.6yrs
          • Compensation: US$34.76k

        Company Information

        Brainstorm Cell Therapeutics Inc.'s company bio, employee growth, exchange listings and data sources


        Key Information

        • Name: Brainstorm Cell Therapeutics Inc.
        • Ticker: BCLI
        • Exchange: NasdaqCM
        • Founded: 2000
        • Industry: Biotechnology
        • Sector: Pharmaceuticals & Biotech
        • Market Cap: US$93.591m
        • Shares outstanding: 22.61m
        • Website: https://www.brainstorm-cell.com

        Number of Employees


        Location

        • Brainstorm Cell Therapeutics Inc.
        • 1325 Avenue of Americas
        • 28th Floor
        • New York
        • New York
        • 10019
        • United States

        Listings

        TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
        BCLINasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDMay 2003
        GHDNDB (Deutsche Boerse AG)YesCommon StockDEEURMay 2003

        Biography

        Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of central nervous system (CNS) adult stem cell therapies designed to address the unmet medical needs of patients with debilitating neurodegenerative diseases. The company holds rights to develop and commercialize its NurOwn technology that utilizes a patient’s own cells, which are engineered outside the body, to produce and secrete factors known to promote neuronal survival. It is developing NurOwn for various neurodegenerative diseases, including its lead indication, which is in Phase III clinical trial for the treatment of amyotrophic lateral sclerosis, as well as in Phase II for the treatment of multiple sclerosis, and preclinical trial for Parkinson’s disease, Huntington’s disease, and autism spectrum disorder. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004 to reflect its new line of business in the development of novel cell therapies for neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in New York, New York. 


        Company Analysis and Financial Data Status

        All financial data provided by Standard & Poor's Capital IQ.
        DataLast Updated (UTC time)
        Company Analysis2020/01/26 00:11
        End of Day Share Price2020/01/24 00:00
        Earnings2019/09/30
        Annual Earnings2018/12/31


        Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.